Scale of health: Indices of safety and efficacy in the evolving environment of large biological datasets

Pharmaceutical Research

Volumn 31, Issue 9, 2014, Pages 2256-2265

  Sayes, Christie M ^a   Staats, Herman ^b   Hickey, Anthony J ^a  

^a RTI INTERNATIONAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

drugs; immunity; inflammation; nanoparticles; vaccines

Indexed keywords

NANOPARTICLE;

ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; FACTUAL DATABASE; HUMAN; INFLAMMATION; INNATE IMMUNITY; METABOLISM; NANOMEDICINE; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; DATABASES, FACTUAL; HUMANS; IMMUNITY, INNATE; INFLAMMATION; NANOMEDICINE; NANOPARTICLES; SIGNAL TRANSDUCTION;

EID: 84930371093     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1415-2     Document Type: Review

References (57)

1. Dobrovolskaia MA, Germolec DR, Weaver JL. Evaluation of nanoparticle immunotoxicity. Nat Nanotechnol. 2009;4(7):411-4.
2. Dobrovolskaia, M.A. and S.E. McNeil, Immunological properties of engineered nanomaterials. Nature Nanotechnology, 2007. 2 (August).
3. Dreher KL. Health and environmental impact of nanotechnology: toxicological assessment of manufactured nanoparticles. Toxicol Sci. 2004;77:3-5.
4. Garcia-Contreras L et al. Immediate and short-term cellular and biochemical responses to pulmonary single-dose studies of insulin and H-MAP. Pharm Res. 2001;18:1685-93.
5. Li R et al. Surface charge and cellular processing of covalently functionalized multiwall carbon nanotubes determine pulmonary toxicity. ACS Nano. 2013;7(3):2352-68.
6. Schanen BC et al. Immunomodulation and T helper TH (1)/TH (2) response polarization by CeO (2) and TiO (2) nanoparticles. PLoS One. 2013;8(5):e62816.
7. Schanen BC et al. Exposure to titanium dioxide nanomaterials provokes inflammation of an in vitro human immune construct. ACS Nano. 2009;3(9):2523-32.
8. Lu D et al. Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B. Pharm Res. 2007;24:1834-43.
9. Pettis RJ, Hickey AJ. Aerosol delivery of peptide immunomodulators to rodent lungs. In: Tam JP, Kaumaya PTP, editors. Peptides frontiers of peptide science. Norwell: Kluwer/ESCOM; 1999. p. 845-6.
10. Tsai MY et al. Effect of influenza vaccine on markers of inflammation and lipid profile. J Lab Clin Med. 2005;145(6):323-7.
11. Protection, I.C.o.R., Recommendations of the ICRP. 1964, International Commission on Radiation Protection Oxford.
12. Oberdörster, G., O. E., and J. Oberdörster, Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles. Environmental Health Perspectives, 2005. 113(7): p. 823.
13. Kirchner C et al. Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. Nano Lett. 2005;5(2):331-8.
14. Gopee N et al. Migration of intradermally injected quantum dots to sentinel organs in mice. Toxicol Sci. 2007;98(1):249-57.
15. Zhang L, Monteiro-Riviere N. Assessment of quantum dot penetration into intact, tape-stripped, abraded and flexed rat skin. Skin Pharmacol Physiol. 2008;21(3):166-80.
16. Zhang Y, Kohler N, Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials. 2002;23(7):1553-61.
17. Kukowska-Latallo JF et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005;65(12):5317-24.
18. Farokhzad OC et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103(16):6315-20.
19. Delehanty JB et al. Self-assembled quantum dot-peptide bioconjugates for selective intracellular delivery. Bioconjug Chem. 2006;17(4):920-7.
20. Gref R et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B: Biointerfaces. 2000;18(3-4):301-13.
21. Moore A, Weissleder R, Bogdanov A. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging. 1997;7(6):1140-5.
22. Zahr A, Davis C, Pishko M. Macrophage uptake of core-shell nanoparticles surface modified with poly (ethylene glycol). Langmuir. 2006;22:8178.
23. Berg JM et al. The relationship between pH and Zeta potential of ~30 nm metal oxide nanoparticle suspensions relevant to in vitro toxicological evaluations. Nanotoxicology. 2009;3(4):276-83.
24. Sayes CM, Reed KL, Warheit DB. Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. Toxicol Sci. 2007;97(1):163-80.
25. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34(5):637-50.
26. St John AL, Abraham SN. Innate immunity and its regulation by mast cells. J Immunol. 2013;190(9):4458-63.
27. Tait Wojno ED, Artis D. Innate lymphoid cells: balancing immunity, inflammation, and tissue repair in the intestine. Cell Host Microbe. 2012;12(4):445-57.
28. Olive C. Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants. Ext Rev. 2012;11(2):237-56.
29. Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol. 2012;12(7):479-91.
30. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327(5963):291-5.
31. Marichal T et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med. 2011;17(8):996-1002.
32. Tewary P. Beta-defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN-alpha production by human plasmacytoid dendritic cells, and promote inflammation. J Immunol. 2013;19(2):865-74.
33. Yasuda K et al. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J Immunol. 2005;174(10):6129-36.
34. Chang H et al. Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation. Exp Toxicol Pathol. 2013;65(6):887-96.
35. Sun, B., et al., Engineering an Effective Immune Adjuvant by Designed Control of Shape and Crystallinity of Aluminum Oxyhydroxide Nanoparticles. ACS Nano, 2013.
36. Katwa P et al. A carbon nanotube toxicity paradigm driven by mast cells and the IL-(3) (3)/ST (2) axis. Small. 2012;8(18):2904-12.
37. Worthington KL et al. Chitosan coating of copper nanoparticles reduces in vitro toxicity and increases inflammation in the lung. Nanotechnology. 2013;24(39):395101.
38. Noah TL et al. Nasal cytokine production in viral acute upper respiratory infection of childhood. J Infect Dis. 1995;171(3):584-92.
39. Moro MR et al. Clinical features, adenovirus types, and local production of inflammatory mediators in adenovirus infections. Pediatr Infect Dis J. 2009;28(5):376-80.
40. Laham FR et al. LDH concentration in nasal-wash fluid as a biochemical predictor of bronchiolitis severity. Pediatrics. 2010;125(2):e225-33.
41. Semmler-Behnke M et al. Efficient elimination of inhaled nanoparticles from the alveolar region: evidence for interstitial uptake and subsequent reentrainment onto airway epithelium. Environ Health Perspect. 2007;115(5):728-33.
42. Oberdorster G, Elder A, Rinderknecht A. Nanoparticles and the brain: cause for concern? J Nanosci Nanotechnol. 2009;9(8):4996-5007.
43. Moller W et al. Deposition, retention, and translocation of ultrafine particles from the central airways and lung periphery. Am J Respir Crit Care Med. 2008;177(4):426-32.
44. Geiser M et al. The role of macrophages in the clearance of inhaled ultrafine titanium dioxide particles. Am J Respir Cell Mol Biol. 2008;38(3):371-6.
45. Hellstrand E et al. Complete high-density lipoproteins in nanoparticle corona. FEBS J. 2009;276(12):3372-81.
46. Lundqvist M et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. PNAS USA. 2008;105(38):14265-70.
47. Dawson KA, Salvati A, Lynch I. Nanoparticles reconstruct lipids. Nat Nanotechnol. 2009;4(2):84-5.
48. Gao D et al. Bioeliminable Nanohydrogels for drug delivery. Nano Lett. 2008;8(10):3320-4.
49. Hickey AJ, Smyth HDC. Pharmaco-complexity. New York: Springer; 2011.
50. Cheng J et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28(5):869-76.
51. Wang X et al. Poly (γ-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine. J Med Virol. 2008;80(1):11-9.
52. Kalkanidis M et al. Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods. 2006;40(1):20-9.
53. Conway MA et al. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine. 2001;19(15-16):1940-50.
54. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol. 1999;17:1075.
55. Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis. 1999;5(4):285-94.
56. Ankley G. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem. 2010;29(3):730-41.
57. Schultz, T.W., B. Diderich, and S. Enoch, The OECD adverse outcome pathway approach: A case study for skin sensitization, in AXLR8-2 Workshop Report, T. Seidle and H. Spielmann, Editors. 2011, OECD: http://axlr8.eu/assets/axlr8-progress-report-2011.pdf. p. 288-300.